Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multilocus genetic profiling to empower drug trials and predict brain atrophy

1 Jan 2013

Abstract excerpt

Designers of clinical trials for Alzheimer's disease (AD) and mild cognitive impairment (MCI) are actively considering structural and functional neuroimaging, cerebrospinal fluid and genetic biomarkers to reduce the sample sizes needed to detect therapeutic effects. Genetic pre-selection, however, has been limited to Apolipoprotein E (ApoE). Recently discovered polymorphisms in the CLU, CR1 and PICALM genes are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Bioinformatics and Genomic Networks
Share to Dementia and Cognitive Impairment Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24179834
DOI: 10.1016/j.nicl.2013.05.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multilocus genetic profiling to empower drug trials and predict brain atrophyPMID 24179834Read ↗

Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plansSemantic proximity Read ↗

Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals.Semantic proximity Read ↗

The Radiogenomics of Late-onset Alzheimer Disease.Semantic proximity Read ↗

Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers.Semantic proximity Read ↗

Genetic variation and neuroimaging measures in Alzheimer disease.Semantic proximity Read ↗

Effect of CR1 Genetic Variants on Cerebrospinal Fluid and Neuroimaging Biomarkers in Healthy, Mild Cognitive Impairment and Alzheimer's Disease Cohorts.Semantic proximity Read ↗

An Alzheimer's Disease Genetic Risk Score Predicts Longitudinal Thinning of Hippocampal Complex Subregions in Healthy Older Adults.Semantic proximity Read ↗

A Network of Genetic Effects on Non-Demented Cognitive Aging: Alzheimer's Genetic Risk (CLU + CR1 + PICALM) Intensifies Cognitive Aging Genetic Risk (COMT + BDNF) Selectively for APOEɛ4 Carriers.Semantic proximity Read ↗

Impacts of CR1 genetic variants on cerebrospinal fluid and neuroimaging biomarkers in alzheimer's disease.Semantic proximity Read ↗

Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans.Semantic proximity Read ↗

The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects.Semantic proximity Read ↗

Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.